{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 55,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Clinical trial design flow chart.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/23",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "Study design flow from eligibility to randomization, neoadjuvant treatment, radical cystectomy, and adjuvant treatment.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ceece8e-bd57-46ae-8e35-64926e3a88df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.72,
        "y": 0.275
      },
      "kind": "list",
      "text": "Dual primary endpoints: EFS using BICR or central pathology review; pCR by blinded central pathology review. Key secondary endpoints: OS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50cf7845-4157-4f15-a9a1-767387dd5cbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.05,
        "y": 0.315
      },
      "kind": "list",
      "text": "Cisplatin-eligible MIBC (cT2–T4aN0/1M0); UC or UC with divergent differentiation; Evaluated and confirmed for RC; CrCl of ≥40 mL/min",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c133346c-0897-46cc-a763-13ca69429768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Powles TB et al. Abstract LBA5 presented at the European Society of Medical Oncology 2024.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16a0cc5c-6965-4e42-9f0b-d618a04d7e73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "NIAGARA is Phase III trial of patients with cisplatin-eligible MIBC who were planned for radical cystectomy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb85a4be-de39-4190-b526-b6ddf48a221f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "bb7278c7-fe19-4acd-9f8e-2a3bf7f99067",
      "evidence": "diagram/process: Study design flow from eligibility to randomization, neoadjuvant treatment, radical cystectomy, and adjuvant treatment.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "8b326c42-72ff-4b9b-a83d-11d9f2c886f4",
      "evidence": "Standardized flow chart for clinical trial methodology",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 23,
      "beatId": "ee40693e-a830-4773-906c-580d23182958",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document presents the design and baseline characteristics of the NIAGARA trial.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4",
      "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}